Literature DB >> 7760989

Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies.

J F O'Hanlon1, A Vermeeren, M M Uiterwijk, L M van Veggel, H F Swijgman.   

Abstract

Effects of benzodiazepine (diazepam, lorazepam) and benzodiazepine-like anxiolytics (alpidem, suriclone) and a 5-HT-3 antagonist (ondansetron) on actual driving performance were measured in three double-blind, placebo-controlled studies. Subjects were healthy volunteers in two and anxious patients in the third. Treatments lasted for 8 days. Standardized testing occurred within the first full day and on the last day of treatment. No important differences existed between volunteers' and patients' baseline and/or placebo performances and both groups responded similarly to comparable drugs/doses. Benzodiazepine and benzodiazepine-like anxiolytics produced marked and pervasive driving impairment, which lasted throughout treatment; but ondansetron, none.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7760989     DOI: 10.1159/000119177

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  22 in total

1.  Can the MSLT be a useful tool to assess motor vehicle crash risk in sleepy drivers?

Authors:  Pierre Philip
Journal:  Sleep       Date:  2010-06       Impact factor: 5.849

Review 2.  Benzodiazepine use and motor vehicle accidents. Systematic review of reported association.

Authors:  R E Thomas
Journal:  Can Fam Physician       Date:  1998-04       Impact factor: 3.275

3.  Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg.

Authors:  Tim R M Leufkens; Annemiek Vermeeren; Beitske E Smink; Peter van Ruitenbeek; Johannes G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

4.  Driving simulator performance in patients with possible and probable Alzheimer's disease.

Authors:  Anthony C Stein; Richard M Dubinsky
Journal:  Ann Adv Automot Med       Date:  2011

5.  Validity and reliability of a driving simulator for evaluating the influence of medicinal drugs on driving performance.

Authors:  Mari Iwata; Kunihiro Iwamoto; Iwao Kitajima; Takasuke Nogi; Koichi Onishi; Yu Kajiyama; Izumi Nishino; Masahiko Ando; Norio Ozaki
Journal:  Psychopharmacology (Berl)       Date:  2020-11-24       Impact factor: 4.530

Review 6.  Residual effects of hypnotics: epidemiology and clinical implications.

Authors:  Annemiek Vermeeren
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors.

Authors:  Anne M Hausken; Kari Furu; Svetlana Skurtveit; Anders Engeland; Jørgen G Bramness
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

Review 8.  Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review.

Authors:  Toni M Rudisill; Motao Zhu; George A Kelley; Courtney Pilkerton; Brandon R Rudisill
Journal:  Accid Anal Prev       Date:  2016-08-29

9.  Effects of word frequency on recall memory following lorazepam, alcohol, and lorazepam alcohol interaction in healthy volunteers.

Authors:  Sompop Soo-ampon; Noppamars Wongwitdecha; Surin Plasen; Ian Hindmarch; Julia Boyle
Journal:  Psychopharmacology (Berl)       Date:  2004-04-29       Impact factor: 4.530

10.  Testing for benzodiazepine inebriation--relationship between benzodiazepine concentration and simple clinical tests for impairment in a sample of drugged drivers.

Authors:  Jørgen G Bramness; Svetlana Skurtveit; Jørg Mørland
Journal:  Eur J Clin Pharmacol       Date:  2003-09-20       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.